Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Protein biomarkers accurately and quickly diagnose ALS, find Pittsburgh researchers

17.11.2003


Proteomic signature for ALS identified



Detection of protein abnormalities in cerebrospinal fluid (CSF) of patients with amyotrophic lateral sclerosis (ALS) may allow physicians to more rapidly diagnose and better monitor drug efficacy in clinical trials for the disease, according to a novel study presented by a University of Pittsburgh researcher in Milan, Italy, today.

These findings may lead to the first test for early stage ALS, also know as Lou Gehrig’s disease.


The study, presented by Robert Bowser, Ph.D., of the University of Pittsburgh School of Medicine at the 11th annual meeting of the International Alliance of ALS/MND Associations and 14th International Symposium on ALS/MND, identified ALS-specific biomarkers by protein profiling of cerebrospinal fluid from 25 ALS patients and 35 control subjects.

"There are no known diagnostic biomarkers for ALS and no sensitive methods to determine whether a particular drug is working in an ALS patient, nor any way to best test drug combinations for effectiveness," said Dr. Bowser, who is associate professor of pathology and director of the ALS Tissue Bank at the University of Pittsburgh School of Medicine. "A panel of biomarkers would not only be useful in a more rapid diagnosis of ALS, but also would be a valuable tool to evaluate drug efficacy in clinical trials. Protein profiling may also identify biochemical pathways leading to cell death and new therapeutic targets."

CSF samples were obtained from recently diagnosed ALS patients and control subjects who did not have ALS. Some control subjects had no neurologic symptoms, while others had neurological diseases (including four with peripheral neuropathies, one with myopathy, one with probable Alzheimer’s, one with demyelinating disorder, one with meningitis and one with autoimmune sensory motor axonopathy). CSF was used because it is in close contact with motor neurons and brain cells called glia affected by ALS and therefore may harbor high concentrations of diagnostic biomarkers.

Using mass spectrometry to characterize protein peaks that exhibit statistically significant alterations between ALS patients and the control groups, Dr. Bowser and his colleagues identified protein biomarkers that diagnose ALS with near 100 percent specificity and sensitivity.

"Not only will a CSF-based test lead to faster diagnosis, it will permit physicians to monitor the patient during drug treatment and determine whether any of the protein abnormalities that have occurred in the patient have been reduced due to drug treatment. By monitoring the biomarkers, we will be able to directly monitor drug efficacy. By using data from multiple clinical trials, we can determine the best drug combination to offer ALS patients," Dr. Bowser said.

"This research is at the forefront of ALS research. Our next step is to confirm our results with a larger patient population and further evaluate how the biomarker signature pattern changes during disease progression," he said.


The International Symposium on ALS/MND brings together leading international scientists, clinicians and health and social care professionals to present and debate key innovations in their respective fields. The symposium is planned as two parallel meetings, one on biomedical science and the other on research and advances in the care and management of people affected by ALS/MND.

Dr. Bowser’s research is in collaboration with investigators at Massachusetts General Hospital/ Harvard.

ALS is a fatal neurodegenerative disease that attacks nerve cells and pathways in the brain and spinal cord. When cells die, voluntary muscle control and movement is lost. Those patients in the later stages of the disease are totally paralyzed even though their minds remain alert. The average life expectancy of a person with ALS is between two to five years from time of diagnosis.

Frank Raczkiewicz | EurekAlert!
Further information:
http://www.upmc.edu/

More articles from Health and Medicine:

nachricht Purdue cancer identity technology makes it easier to find a tumor's 'address'
16.11.2018 | Purdue University

nachricht Microgel powder fights infection and helps wounds heal
14.11.2018 | Michigan Technological University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: UNH scientists help provide first-ever views of elusive energy explosion

Researchers at the University of New Hampshire have captured a difficult-to-view singular event involving "magnetic reconnection"--the process by which sparse particles and energy around Earth collide producing a quick but mighty explosion--in the Earth's magnetotail, the magnetic environment that trails behind the planet.

Magnetic reconnection has remained a bit of a mystery to scientists. They know it exists and have documented the effects that the energy explosions can...

Im Focus: A Chip with Blood Vessels

Biochips have been developed at TU Wien (Vienna), on which tissue can be produced and examined. This allows supplying the tissue with different substances in a very controlled way.

Cultivating human cells in the Petri dish is not a big challenge today. Producing artificial tissue, however, permeated by fine blood vessels, is a much more...

Im Focus: A Leap Into Quantum Technology

Faster and secure data communication: This is the goal of a new joint project involving physicists from the University of Würzburg. The German Federal Ministry of Education and Research funds the project with 14.8 million euro.

In our digital world data security and secure communication are becoming more and more important. Quantum communication is a promising approach to achieve...

Im Focus: Research icebreaker Polarstern begins the Antarctic season

What does it look like below the ice shelf of the calved massive iceberg A68?

On Saturday, 10 November 2018, the research icebreaker Polarstern will leave its homeport of Bremerhaven, bound for Cape Town, South Africa.

Im Focus: Penn engineers develop ultrathin, ultralight 'nanocardboard'

When choosing materials to make something, trade-offs need to be made between a host of properties, such as thickness, stiffness and weight. Depending on the application in question, finding just the right balance is the difference between success and failure

Now, a team of Penn Engineers has demonstrated a new material they call "nanocardboard," an ultrathin equivalent of corrugated paper cardboard. A square...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

“3rd Conference on Laser Polishing – LaP 2018” Attracts International Experts and Users

09.11.2018 | Event News

On the brain’s ability to find the right direction

06.11.2018 | Event News

European Space Talks: Weltraumschrott – eine Gefahr für die Gesellschaft?

23.10.2018 | Event News

 
Latest News

NASA keeps watch over space explosions

16.11.2018 | Physics and Astronomy

UNH scientists help provide first-ever views of elusive energy explosion

16.11.2018 | Physics and Astronomy

How the gut ‘talks’ to brown fat

16.11.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>